Method for treating complementary determining regions 3 (CDRs3) of B cell antigen receptor H chains

Abstract

The invention relates to a method for treating complementary determining regions 3 (CDRs3) of B cell antigen receptor H chains. The method comprises the following steps: setting an experimental group and a control group, wherein each group comprises a plurality of parts of peripheral blood samples which are dissimilar to a human body and get away from the human body; separating B cells of the peripheral blood samples, and respectively extracting deoxyribonucleic acid (DNA) in the B cells of the peripheral blood samples; adopting a multiplex polymerase chain reaction (PCR) technique to amplify the CDRs3 of the B cell antigen receptor H chains; carrying out high-throughput sequencing on the CDRs3 of the B cell antigen receptor H chains, and carrying out DNA analysis on the B cell antigen receptor H chains in the experimental group and the control group. The method for treating the CDRs3 of the B cell antigen receptor H chains is reasonable and feasible in design, and can be used for effectively acquiring information, taken as intermediate results, about renal transplant recipients at the perioperative period and further verifying, analyzing and researching the information so as to help to study the pathogenesis of a rejection reaction and guide the individual rational application of immunosuppressive drugs, thus being beneficial to improvement of the treatment of patients with end-stage renal disease.

Description

technical field [0001] The invention relates to a method for acquiring end-stage renal disease information as an intermediate result, in particular to a processing method for B cell antigen receptor H chain CDR3. Background technique [0002] End stage renal disease (ESRD) refers to the end stage of various chronic kidney diseases. It is similar to the concept of uremia, but the diagnostic criteria are different. It is generally believed that when the ball filtration rate drops to 15mL / (min.1.73m 2 ) can be diagnosed below. That is to say, when chronic kidney disease reaches stage 5, it enters the stage of end-stage renal disease. Patients with ESRD are often accompanied by extremely low immune function, and severe infection is the main reason for their poor quality of life and death. Therefore, understanding the immune status of patients with chronic renal insufficiency at different stages is of great significance for clinical guidance. There may be no obvious discomfort...

AI Technical Summary

Problems solved by technology

However, the above studies have not fully elucidated the immune mechanism of ESRD, and the treatment methods have not fundamentally changed.

Images